MA45244A - Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 - Google Patents
Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1Info
- Publication number
- MA45244A MA45244A MA045244A MA45244A MA45244A MA 45244 A MA45244 A MA 45244A MA 045244 A MA045244 A MA 045244A MA 45244 A MA45244 A MA 45244A MA 45244 A MA45244 A MA 45244A
- Authority
- MA
- Morocco
- Prior art keywords
- substituted pyridines
- pyridines used
- dnmt1 inhibitors
- dnmt1
- inhibitors
- Prior art date
Links
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 title 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349227P | 2016-06-13 | 2016-06-13 | |
| US201662393256P | 2016-09-12 | 2016-09-12 | |
| US201662412343P | 2016-10-25 | 2016-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45244A true MA45244A (fr) | 2019-04-17 |
Family
ID=59239935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045244A MA45244A (fr) | 2016-06-13 | 2017-06-13 | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10975056B2 (enExample) |
| EP (1) | EP3468953B1 (enExample) |
| JP (1) | JP7051829B2 (enExample) |
| KR (1) | KR20190017030A (enExample) |
| CN (1) | CN109563043B (enExample) |
| AU (1) | AU2017283790B2 (enExample) |
| CA (2) | CA3026211A1 (enExample) |
| CL (1) | CL2018003577A1 (enExample) |
| CO (1) | CO2018013717A2 (enExample) |
| CR (1) | CR20180580A (enExample) |
| DO (1) | DOP2018000273A (enExample) |
| ES (1) | ES2993451T3 (enExample) |
| IL (1) | IL263163B (enExample) |
| JO (1) | JOP20180120A1 (enExample) |
| MA (1) | MA45244A (enExample) |
| MX (1) | MX391600B (enExample) |
| PE (1) | PE20190971A1 (enExample) |
| PH (1) | PH12018502633B1 (enExample) |
| SG (1) | SG11201809559UA (enExample) |
| WO (2) | WO2017216727A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
| BR112018075734A2 (pt) | 2016-06-13 | 2019-04-02 | Gilead Sciences, Inc. | composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto. |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds |
| US10414747B2 (en) | 2016-10-04 | 2019-09-17 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene compounds as sting agonists |
| CN110461328A (zh) | 2017-03-28 | 2019-11-15 | 吉利德科学公司 | 治疗肝疾病的治疗组合 |
| WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| WO2019072143A1 (zh) * | 2017-10-11 | 2019-04-18 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
| EP3727401A4 (en) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| EP3774764A1 (en) | 2018-04-03 | 2021-02-17 | Merck Sharp&Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
| EP4360632B1 (en) | 2019-01-15 | 2025-10-29 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
| CN113480541B (zh) * | 2019-03-07 | 2022-09-02 | 湖南化工研究院有限公司 | 咪唑并吡啶化合物及其中间体的制备方法 |
| US20240002396A1 (en) * | 2020-10-07 | 2024-01-04 | University Of Florida Research Foundation, Incorporated | Macrocyclic compounds and methods of treatment |
| CA3212345A1 (en) | 2021-03-02 | 2022-09-09 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
| CN113502265B (zh) * | 2021-05-25 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 将t细胞重编程为类nk细胞的诱导剂及其应用 |
| CN113278021B (zh) * | 2021-05-29 | 2022-09-23 | 天津全和诚科技有限责任公司 | 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法 |
| CN118354759A (zh) | 2021-10-19 | 2024-07-16 | 阿基拉比奥有限公司 | 包含2’-脱氧胞苷类似物的组合物及其用于治疗镰状细胞病、地中海贫血和癌症的用途 |
| CN114230459A (zh) * | 2021-12-10 | 2022-03-25 | 武汉九州钰民医药科技有限公司 | 一种化合物的制备方法及分析检测方法 |
| WO2023192629A1 (en) * | 2022-04-01 | 2023-10-05 | Herophilus, Inc. | Induction of mecp2 expression by dna methyl transferase inhibitors |
| WO2024156288A1 (en) * | 2023-01-29 | 2024-08-02 | Shanghai Kygent Pharmaceutical Co., Ltd | Dnmt1 inhibitors, pharmaceutical compositions, and therapeutic applications |
| EP4734989A2 (en) * | 2023-06-29 | 2026-05-06 | Dana-Farber Cancer Institute, Inc. | Synthesis and in vitro characterization of proteolysis targeting chimeras (protacs) for degradation of dna methyltransferase 1 (dnmt1) |
| WO2025085756A1 (en) * | 2023-10-18 | 2025-04-24 | University Of Florida Research Foundation, Incorporated | Macrocyclic compounds and methods of treatment |
| WO2025190285A1 (en) * | 2024-03-12 | 2025-09-18 | Shanghai Kygent Pharmaceutical Co., Ltd | Pyridine compounds, pharmaceutical compositions, and applications |
| CN119306700A (zh) * | 2024-08-28 | 2025-01-14 | 山东大学 | Dnmt1-hdac双靶点抑制剂及其制备方法和应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2030875C (en) | 1990-11-26 | 2002-07-02 | Alan R.P. Paterson | Methods and probes for detecting nucleoside transporter and method for producing the probes |
| CA2075154A1 (en) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
| AU6536494A (en) | 1993-03-26 | 1994-10-24 | Shell Internationale Research Maatschappij B.V. | Herbicidal 1-heteroaryl pyrazolidin-3,5-diones |
| CN1209060A (zh) | 1995-12-29 | 1999-02-24 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
| KR19990076877A (ko) | 1995-12-29 | 1999-10-25 | 스티븐 베네티아너 | 비트로넥틴 수용체 길항제 |
| DE19947154A1 (de) | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| CA2394639A1 (en) | 1999-12-15 | 2001-06-21 | Danny Peter Claude Mcgee | Salicylamides as serine protease and factor xa inhibitors |
| US6794506B2 (en) | 2000-07-21 | 2004-09-21 | Elan Pharmaceuticals, Inc. | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
| US20030166554A1 (en) | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| DE10110754A1 (de) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| DE10134481A1 (de) * | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| DE10238113A1 (de) * | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| TW200406370A (en) | 2002-06-28 | 2004-05-01 | Syngenta Participations Ag | 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives |
| AR043048A1 (es) | 2002-08-30 | 2005-07-13 | Syngenta Participations Ag | Derivados de 4-(3,3-dihalo- aliloxi) fenol con propiedades pesticidas |
| US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
| TW200410632A (en) | 2002-12-11 | 2004-07-01 | Syngenta Participations Ag | Dihalo-allyloxy-phenol derivatives having pesticidal activity |
| SE0203712D0 (sv) | 2002-12-13 | 2002-12-13 | Astrazeneca Ab | Novel compounds |
| WO2004092196A2 (en) | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| ATE556067T1 (de) | 2003-05-20 | 2012-05-15 | Ajinomoto Kk | Modulatoren des vanilloid rezeptors |
| CA2539707C (en) | 2003-09-23 | 2011-08-09 | Merck & Co., Inc. | Quinoline potassium channel inhibitors |
| AU2011253934C1 (en) | 2004-06-17 | 2013-08-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| EP1655296A1 (en) | 2004-10-25 | 2006-05-10 | Graffinity Pharmaceuticals AG | Thrombin inhibitors |
| EP1844062A2 (en) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| ZA200810739B (en) | 2006-06-20 | 2010-03-31 | Ishihara Sangyo Kaisha | Pesticide containing novel pyridyl-methanamine derivative or its salt |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| KR20090104920A (ko) | 2007-02-01 | 2009-10-06 | 아스트라제네카 아베 | Ｈｓｐ90 억제제로서 5,6,7,8-테트라히드로프테리딘 유도체 |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| WO2009034433A2 (en) | 2007-09-10 | 2009-03-19 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| ES2446932T3 (es) | 2007-10-08 | 2014-03-10 | Advinus Therapeutics Private Limited | Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina |
| US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| WO2010007756A1 (ja) | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Ｔｔｋ阻害作用を有するピリジン誘導体 |
| WO2010020810A1 (en) | 2008-08-19 | 2010-02-25 | Astrazeneca Ab | 2-(imidaz0lylamin0)-pyridine derivatives and their use as jak kinase inhibitors |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| KR101146010B1 (ko) * | 2009-09-10 | 2012-05-16 | 서울대학교산학협력단 | ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물 |
| WO2011058763A1 (ja) | 2009-11-13 | 2011-05-19 | 塩野義製薬株式会社 | アミノリンカーを有するアミノチアジンまたはアミノオキサジン誘導体 |
| BR112012015248B1 (pt) | 2009-12-23 | 2022-01-04 | Jasco Pharmaceuticals, LLC | Composto |
| DK2516434T3 (en) | 2009-12-23 | 2015-08-31 | Takeda Pharmaceutical | FUSED HETEROAROMATIC PYRROLIDINONS AS SICK INHIBITORS |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| WO2011103289A2 (en) | 2010-02-17 | 2011-08-25 | Jasco Pharmaceuticals, LLC | Imidazole-2, 4-dione inhibitors of casein kinase 1 |
| CA2800618C (en) | 2010-05-26 | 2018-08-28 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US9422262B2 (en) | 2010-09-24 | 2016-08-23 | The Broad Institute, Inc. | Compounds and methods for treating diseases mediated by protease activated receptors |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| CN103402359B (zh) | 2011-01-17 | 2016-08-24 | 卡尔约药物治疗公司 | 含烯烃核运输调节剂及其用途 |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US20140155419A1 (en) | 2011-07-29 | 2014-06-05 | Erkan Baloglu | Compounds and methods |
| EP2747560A4 (en) | 2011-07-29 | 2015-02-25 | Tempero Pharmaceuticals Inc | CONNECTIONS AND METHODS |
| US20140357594A1 (en) * | 2011-10-24 | 2014-12-04 | Glaxosmithkline Intellectual Property (No.2) Limited | New compounds |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| EA030253B1 (ru) | 2012-09-28 | 2018-07-31 | Кэнсэр Ресерч Текнолоджи Лимитед | Азахиназолиновые ингибиторы атипичной протеинкиназы c |
| BR112016016853A2 (pt) | 2014-01-21 | 2017-08-08 | Wockhardt Ltd | Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso |
| WO2015110999A1 (en) | 2014-01-24 | 2015-07-30 | Piramal Enterprises Limited | Ezh2 inhibitors and uses thereof |
-
2017
- 2017-06-13 MA MA045244A patent/MA45244A/fr unknown
- 2017-06-13 CN CN201780036908.XA patent/CN109563043B/zh active Active
- 2017-06-13 MX MX2018015483A patent/MX391600B/es unknown
- 2017-06-13 SG SG11201809559UA patent/SG11201809559UA/en unknown
- 2017-06-13 PH PH1/2018/502633A patent/PH12018502633B1/en unknown
- 2017-06-13 KR KR1020197000766A patent/KR20190017030A/ko not_active Ceased
- 2017-06-13 JP JP2019517187A patent/JP7051829B2/ja active Active
- 2017-06-13 CA CA3026211A patent/CA3026211A1/en active Pending
- 2017-06-13 WO PCT/IB2017/053511 patent/WO2017216727A1/en not_active Ceased
- 2017-06-13 PE PE2018003216A patent/PE20190971A1/es unknown
- 2017-06-13 WO PCT/IB2017/053509 patent/WO2017216726A1/en not_active Ceased
- 2017-06-13 CA CA3026226A patent/CA3026226A1/en not_active Abandoned
- 2017-06-13 CR CR20180580A patent/CR20180580A/es unknown
- 2017-06-13 US US16/309,121 patent/US10975056B2/en active Active
- 2017-06-13 ES ES17733902T patent/ES2993451T3/es active Active
- 2017-06-13 AU AU2017283790A patent/AU2017283790B2/en not_active Ceased
- 2017-06-13 EP EP17733902.5A patent/EP3468953B1/en active Active
-
2018
- 2018-11-21 IL IL263163A patent/IL263163B/en unknown
- 2018-12-07 DO DO2018000273A patent/DOP2018000273A/es unknown
- 2018-12-10 JO JOP/2018/0120A patent/JOP20180120A1/ar unknown
- 2018-12-12 CL CL2018003577A patent/CL2018003577A1/es unknown
- 2018-12-18 CO CONC2018/0013717A patent/CO2018013717A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190017030A (ko) | 2019-02-19 |
| CL2018003577A1 (es) | 2019-04-05 |
| IL263163A (en) | 2018-12-31 |
| EP3468953C0 (en) | 2024-05-22 |
| WO2017216727A1 (en) | 2017-12-21 |
| CA3026226A1 (en) | 2017-12-21 |
| AU2017283790B2 (en) | 2019-08-29 |
| MX2018015483A (es) | 2019-03-18 |
| CN109563043A (zh) | 2019-04-02 |
| PE20190971A1 (es) | 2019-07-09 |
| IL263163B (en) | 2021-10-31 |
| JOP20180120A1 (ar) | 2019-01-30 |
| AU2017283790A1 (en) | 2018-11-22 |
| DOP2018000273A (es) | 2019-03-31 |
| WO2017216726A1 (en) | 2017-12-21 |
| JP2019517596A (ja) | 2019-06-24 |
| EP3468953A1 (en) | 2019-04-17 |
| CO2018013717A2 (es) | 2019-01-18 |
| JP7051829B2 (ja) | 2022-04-11 |
| SG11201809559UA (en) | 2018-12-28 |
| PH12018502633A1 (en) | 2019-09-30 |
| US10975056B2 (en) | 2021-04-13 |
| CN109563043B (zh) | 2022-05-31 |
| ES2993451T3 (en) | 2024-12-30 |
| BR112018075992A2 (pt) | 2019-04-02 |
| CA3026211A1 (en) | 2017-12-21 |
| CR20180580A (es) | 2019-07-02 |
| MX391600B (es) | 2025-03-21 |
| US20190194166A1 (en) | 2019-06-27 |
| EP3468953B1 (en) | 2024-05-22 |
| PH12018502633B1 (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| EP3386981A4 (en) | HETEROCYCLES SUITABLE AS ANTICROGEN | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
| MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg | |
| EP3533787A4 (en) | PYRIDONE COMPOUND AS A C-MET INHIBITOR | |
| MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
| EP3416964A4 (en) | Carboxamide derivatives as RSK inhibitors | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| FR25C1047I1 (fr) | Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 |